Resource

 

 

 

 

 

 

 

 

 

 

 

JV/Alliance/Licence

Infrastructure experts advise Canberra Metro on successful bid for ACT Capital Metro light rail project

03 Feb 2016

Herbert Smith Freehills has advised the Canberra Metro consortium (Canberra Metro) on its successful bid for the Australian Capital Territory Capital Metro light rail project.

Canberra Metro will finance, design and construct the project and then operate and maintain the 12km light rail route from the fast growing area of Gungahlin - in Canberra’s northern suburbs - to the CBD. Canberra Metro aims to have the light rail system operational in early 2019.

Simmons & Simmons Advises GlaxoSmithKline on Ground-breaking Joint Venture Investment Fund

29 Jan 2016

Simmons & Simmons has advised GlaxoSmithKline (GSK) on the establishment of an innovative joint venture investment fund.

The joint venture fund has been established through a limited liability partnership entity under the name Apollo Therapeutics LLP between GlaxoSmithKline, Johnson & Johnson Innovation and AstraZeneca, Imperial Innovations, UCL Business and Cambridge Enterprise.

Clifford Chance advises Allianz on a joint venture in Austria

29 Jan 2016

Clifford Chance has advised Allianz Real Estate Germany GmbH on the establishment of a joint venture between affiliates of the Allianz Group and a real estate vehicle of the Austrian company SES Spar European Shopping Centers GmbH for the purpose of acquiring the "Fischapark" shopping centre in Wiener Neustadt, Austria.

By acquiring a share in "Fischapark", Allianz complemented an existing joint venture with SES established in 2013 which has a portfolio comprising seven other shopping centres in Austria, Italy and Slovakia (the "Senza Confini Portfolio"). 

DLA Piper advises Tissue Regenix on the forming of a Joint Venture with GTM-V

28 Jan 2016

DLA Piper has successfully advised Tissue Regenix Goup plc. (Tissue Regenix) on a joint venture agreement with the German Gesellschaft für Transplantationsmedizin gemeinnützige GmbH (GTM-V) to form GBM-V gemeinnützige GmbH ("GBM-V"), a tissue bank based in Rostock, Germany. This is the first joint venture contract for GTM-V with Tissue Regenix, which patented the human ‘dCELL® technology; a technology that can remove DNA from animal and human tissue.

Mayer Brown represents Nestlé Health Science in major biotech licensing and collaboration transaction

26 Jan 2016

Mayer Brown represented Nestlé Health Science in a licensing and collaboration transaction with Seres Therapeutics to develop and commercialize drugs based on the human microbiome for inflammatory bowel disease and Clostridium difficile. Under the agreement, Nestlé obtained rights to the covered products outside the US and Canada in return for an upfront payment of $120 million and contingent payments linked to the achievement of development and sales-based milestones, as well as royalties on future net sales.

WOLF THEISS SUCCESSFULLY ADVISED ERG RENEW AND LUKOIL ON THE MUTUAL SEPARATION OF THE LUKERG RENEW JV

26 Jan 2016

Vienna, 13.01.2015 – At the end of December, Wolf Theiss successfully advised on the closing of the mutual separation of LUKERG Renew, a 50-50 joint venture between ERG Renew and LUKOIL. The assets of the joint venture in Bulgaria and Romania have been separated between the two companies.

Smartphones: TDK et Qualcomm form $3bn joint-venture

25 Jan 2016

Japan’s components manufacturer TDK Corp. and American chipmaker Qualcomm Inc. announced an agreement to form a joint-venture to provide industry-leading RF front-end-solutions for mobile devices.

Jeantet assisted TDK together with Morrison Foerster on the French aspects of the transaction with Karl Hepp de Sevelinges, partner, and Ingrid Fauvelière, counsel (M&A).

Qualcomm was advised by DLA Piper